AOP and Lantibio report positive safety results on Moli1901

Germany's AOP Orphan Pharmaceuticals AG and USA-based Lantibio have reported positive final results from a placebo-controlled, double-blinded Phase II clinical study of Moli1901, an experimental compound to treat cystic fibrosis. The agent is being developed by AOP in Europe under a licensing and commercialization agreement with Lantibio. The safety and tolerability study found that subjects aged 12 years and older tolerated daily administration of Moli1901 over 28 days of daily dosing by the inhalation route and analysis of the data did not reveal unexpected safety concerns.